TY  - BOOK
AU  - Sterckx,Sigrid
AU  - Cockbain,Julian
TI  - Exclusions from Patentability: How Far Has the European Patent Office Eroded Boundaries?
T2  - Cambridge Intellectual Property and Information Law
SN  - 9781139572545
AV  - KJC2725 .S74 2012 
U1  - 346.240486 
PY  - 2012///
CY  - Cambridge
PB  - Cambridge University Press
KW  - European Patent Convention -- (1973)
KW  - European Patent Office
KW  - Patent laws and legislation -- Europe
KW  - Electronic books
N1  - Cover -- Exclusions from Patentability -- Title -- Copyright -- Dedication -- Contents -- Acknowledgements -- Table of cases -- EPO cases -- Enlarged Board of Appeal decisions: -- Technical Board of Appeal decisions: -- Other cases: -- Table of international conventions and regulations -- Table of official documents -- Explanation of document numbering -- Abbreviations -- 1 Introduction -- 1.1 The most basic of the safeguards -- 1.2 The 'New Wealth of Nations' -- 1.3 Natural rights as the foundation for patents? -- 1.4 Distributive justice as the foundation for patents? -- 1.5 Utilitarianism as the foundation for patents? -- 2 The historical development and current scope of the European Patent Convention -- 2.1 Introduction -- 2.2 The international harmonisation of patent law -- 2.3 The early history -- 2.4 Plant variety protection - the negotiations leading to UPOV 1961 -- 2.5 The parallel drafting of the SPC and the CEPL (with UPOV 1961 in the background) -- 2.6 The 1960s pause and the arrival of the PCT -- 2.7 The process restarts -- 2.8 The home straight - the Munich Diplomatic Conference of September/October 1973 -- 2.9 Discontent sets in -- 2.10 The 2000 revision of the EPC -- 3 Computer programs -- 3.1 Introduction -- 3.2 The TBoA 3.5.01 (Electricity I) story -- 3.3 What the other Boards were doing -- 3.3.1 Board 3.4.01 (Physics I) -- 3.3.2 Board 3.2.04 (Mechanics IV) -- 3.3.3 The other Boards -- 3.4 The legislative history -- 3.5 The Enlarged Board Opinion - G-3/08 Programs for computers -- 3.5.1 Should the president's referral have been admitted? -- 3.5.2 The divergent decisions -- 3.5.3 The Enlarged Board's reasoning -- 3.5.4 The questions -- 3.5.4.1 Question 1: Can a computer program only be excluded as a computer program as such if it is explicitly claimed as a computer program -- 3.5.4.2 Questions 2, 3 and 4 -- 3.6 Conclusion; 4 Discoveries -- 4.1 Introduction -- 4.2 T-877/92 Removal of carcinogenic hydrocarbons/EXXON -- 4.3 T-869/95 NISSAN MOTOR -- 4.4 T-272/95 Relaxin/HOWARD FLOREY INSTITUTE -- 4.5 T-338/00 Multimeric receptors/SALK INSTITUTE -- 4.6 T-1538/05 ZAGYANSKY -- 4.7 T-1213/05 Breast and ovarian cancer/ UNIVERSITY OF UTAH -- 4.8 T-666/05 Mutation/UNIVERSITY OF UTAH -- 4.9 T-80/05 Method of diagnosis/UNIVERSITY OF UTAH -- 4.10 Comments -- 5 Methods of medical treatment and diagnosis -- 5.1 Introduction -- 5.2 What is therapy? -- 5.3 What has been found to be, or not to be, therapy? -- 5.4 What is surgery? -- 5.5 The aftermath of the Enlarged Board decision on 'surgery' -- 5.6 What would be found to be or not to be surgery? -- 5.7 What is diagnosis? -- 5.8 What would be found to be or not to be diagnosis? -- 5.9 Does the identity of the performer matter? -- 5.10 What happens when the treatment claimed could overlap with an excluded method? -- 5.11 The travaux préparatoires -- 5.12 The contamination approach -- 5.13 Patenting known drug substances -- 5.13.1 Second and further indications -- 5.13.2 The G-5/83 Second medical indication/EISAI Decision -- 5.13.3 G-2/08 Dosage regime/ABBOTT RESPIRATORY decision -- 5.13.4 The Implications of the G-2/08 Dosage regime/ABBOTT RESPIRATORY decision -- 6 Essentially biological processes for the production of plants and animals -- 6.1 Introduction -- 6.2 The law -- 6.3 The key issues -- 6.4 Key decisions -- 6.5 The travaux préparatoires -- 6.6 Possible types of claims and their acceptability in view of the exclusion -- 6.7 Implications -- 6.8 Products of 'essentially biological processes' -- 6.9 The status quo -- 7 Plant and animal varieties -- 7.1 Introduction -- 7.2 Plants: T-49/83 Propagating material/CIBA-GEIGY -- 7.3 Plants: T-320/87 Hybrid plants/LUBRIZOL -- 7.4 Animals: T-19/90 Onco-mouse/HARVARD; 7.5 Plants: T-356/93 Plant cells/PLANT GENETIC SYSTEMS -- 7.6 Plants: G-3/95 Inadmissible referral -- 7.7 Plants: T-1054/96 (I) Transgenic plant/NOVARTIS -- 7.8 Plants: G-1/98 Transgenic plant/NOVARTIS II -- 7.9 Plants: T-149/98 Resistance development/BAYER -- 7.10 Plants: T-1054/96 Anti-pathogenic compositions/NOVARTIS III -- 7.11 Plants: T-475/01 Phosphinothricin resistant gene/BAYER -- 7.12 Plants: T-179/01 Herbicide resistant plants/MONSANTO -- 7.13 Animals: T-315/03 Transgenic animals/HARVARD -- 7.14 Plants: T-788/07 Brassica/PIONEER -- 7.15 Plants: T-1854/07 Oil from seeds/CONSEJO SUPERIOR -- 7.16 Plants: T-775/08 Glyphosate tolerant alfalfa/MONSANTO -- 7.17 General comments -- 7.17.1 How necessary is product protection? -- 7.17.2 The purpose of the exclusion -- 7.17.3 The meaning of 'varieties' -- 7.17.4 The second half-sentence -- 7.17.5 The approach to the exclusion -- 7.18 Conclusion -- 8 Morality and 'ordre public' -- 8.1 Introduction -- 8.2 Animals: T-19/90 Onco-mouse/HARVARD -- 8.3 Animals: T-315/03 Transgenic animals/HARVARD -- 8.4 Animals: T-606/03 Gene trap/ARTEMIS -- 8.5 Plants: T-356/93 Plant cells/PLANT GENETIC SYSTEMS -- 8.6 Plants: T-475/01 Phosphinothricin resistant gene/BAYER -- 8.7 Plants: T-179/01 Herbicide resistant plants/MONSANTO -- 8.8 Controversial medical intervention: T-866/01 Euthanasia compositions/MICHIGAN STATE UNIVERSITY -- 8.9 Human genes and genetic diagnostic tests: T-272/95 Relaxin/HOWARD FLOREY INSTITUTE -- 8.10 Human genes and genetic diagnostic tests: T-1213/05 Breast and ovarian cancer/UNIVERSITY OF UTAH -- 8.11 Human genes and genetic diagnostic tests: T-666/05 Mutation/UNIVERSITY OF UTAH -- 8.12 Human genes and genetic diagnostic tests: T-80/05 Method of diagnosis/UNIVERSITY OF UTAH -- 8.13 Stem cells/embryos: T-1374/04 (I) Stem cells/WARF -- 8.14 Stem cells/embryos: G-2/06 Use of embryos/WARF; 8.15 Stem cells/embryos: T-522/04 Stem cells/CALIFORNIA -- 8.16 General comments -- 8.16.1 The EPO as a 'moral censor' -- 8.16.2 The relevance of the EBD-derived EPC Rules -- 8.16.3 The necessity to consider the Article, rather than (merely) the Rules -- 8.16.4 The meaning of the Article -- 8.16.4.1 The 2000 amendment of the Article -- 8.16.4.2 The concept of 'morality' -- 8.16.4.3 The concept of 'ordre public' -- 8.16.4.4 The concept of 'exploitation' -- 8.16.5 Taking into account how an invention has been developed -- 8.16.6 Special considerations in cases relating to the human body and its parts -- 9 Towards a coherent interpretation of the exclusions -- 9.1 Introduction -- 9.2 Approaches to the exclusions -- 9.3 Art. 52(2) EPC -- 9.4 The implications of the 'anything added plus a requirement for synergy' approach to Art. 52(2) EPC -- 9.5 The Art. 53 EPC exclusions -- 9.6 The implications of the implicit disclaimer approach to Art. 53 EPC -- 10 Conclusion -- Correspondence from EPO files -- References -- Index
N2  - This book provides the first comprehensive study of what cannot be patented and what should not be patentable in Europe
UR  - https://ebookcentral.proquest.com/lib/buse-ebooks/detail.action?docID=1025027
ER  -